Autopsy report · NCT04099836

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

“low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months before it started.
• Ran for about 2 years 11 months before it stopped.
• 7 participants enrolled.
• Results were posted on the registry 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Duke University

Sponsor type

University, hospital or other

Conditions

Non Small Cell Lung Cancer

Interventions

Atezolizumab; Bevacizumab

Participants

7

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.